Eli Lilly and Co.

Lilly to pay Idaho $13M in drug settlement

October 14, 2009
 IBJ Staff and Associated Press
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of anti-psychotic drug Zyprexa.
More

Lilly to sell Lafayette plant to German firm

October 14, 2009
J.K. Wall
Nearly 700 workers will be offered severance, new jobs
More

Baucus health reform bill would stick Indiana companies with fees

October 10, 2009
 IBJ Staff
The health reform bill sponsored by U.S. Sen. Max Baucus, D-Mont., would help pay for expanded health insurance coverage by levying fees of $13 billion a year on the health care industry. The fees would deliver a hefty bill to just about all of Indiana’s major health care companies. But how they’re reacting to the fees is all over the map.
More

Lilly settles Zyprexa suit with S. Carolina

October 7, 2009
 IBJ Staff
Eli Lilly and Co. has agreed to settle the State of South Carolina's lawsuit that claimed Lilly improperly marketed the antipsychotic drug Zyprexa, according to Bloomberg News.
More

Lilly's win in Evista patent case crucial, analyst says

September 24, 2009
Scott Olson
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major victory for the company, says an analyst who closely follows the pharmaceutical industry.
More

Judge upholds Lilly's Evista patent

September 24, 2009
J.K. Wall
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced late yesterday.
More

Lilly agrees to settle more state Zyprexa suits

September 22, 2009
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
More

Lilly revises playbook in effort to score more 'touchdowns'

September 19, 2009
J.K. Wall
The drugmaker has successfully moved experimental drugs into position to win approval by regulators. But only once in the last four years has a new drug actually made it to market—the industry’s equivalent of getting across the goal line.
More

UPDATE: Pipeline challenges force Lilly restructuring moves

September 14, 2009
J.K. Wall
Since John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the company's business units ups the ante on that bet, while indicating that it isn't working yet.
More

Lilly reorganization to cut 5,500 positions over 2 years

September 14, 2009
J.K. Wall
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central Indiana. But with 13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
More

Local health care industry tries to capitalize on migraine headaches

September 12, 2009
J.K. Wall
Migraines cost American employers $20 billion a year in decreased worker productivity. Such a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
More

Study weakens Lilly's fight against price controls

September 12, 2009
 IBJ Staff
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.
More

Lilly paid doctors to prescribe Zyprexa, notes say

September 8, 2009
 IBJ Staff
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers' program in exchange for prescribing the antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
More

Lilly drops osteoporosis pipeline drug

August 18, 2009
J.K. Wall
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating the company’s attempts to find revenue before losing patent protection on its bestseller.
More

Lilly pays $224,000 to area doctors

August 17, 2009
 IBJ Staff
It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first quarter.
More

Glut of downtown office space grows

August 17, 2009
Cory Schouten
Safeco is leaving a five-building complex on North Meridian Street, and Eli Lilly and Co. has offered for lease its entire four-building Faris campus.

More

Abatement approval paves way for Covance jobs

August 12, 2009
Scott Olson
The Hancock County Council this morning unanimously approved a tax-incentive agreement that should lead Covance Inc. to add 315 jobs at its Greenfield Laboratories.
More

Lilly reorganizes venture capital unitRestricted Content

August 10, 2009
Peter Schnitzler
Eli Lilly and Co. has reorganized its venture capital division and simultaneously poured in an additional $25 million.More

Lilly offering buyouts to 4,000 sales reps

August 4, 2009
Indianapolis-based Eli Lilly and Co. today said it is offering buyouts to its U.S. sales force, with hopes of trimming about 300 sales representatives before a sales restructuring set to begin in January, Reuters reported.
More

Lilly software spinoff Maaguzi sells for $11 millionRestricted Content

August 3, 2009
Chris O'Malley
Investors in a company built around clinical research software bought from Eli Lilly and Co. have found their exit, though it’s far from the lucrative payoff they’d once imagined.
More

Lilly's Effient launch just one of its many challengesRestricted Content

August 3, 2009
Greg Andrews
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
More

Eli Lilly CEO, wife give United Way $1M gift

July 28, 2009
Kathleen McLaughlin
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total of $1 million over the next four years as a “challenge to CEOs and other community leaders to step up their giving.”
More

Eli Lilly CEO, wife give United Way $1M gift

July 28, 2009
Kathleen McLaughlin
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total of $1 million over the next four years as a "challenge to CEOs and other community leaders to step up their giving."
More

Lilly cancels trials for experimental MS drug

July 28, 2009
J.K. Wall
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis after the drug failed to delay progression of the disease in trial patients.
More

BREAKING: FDA approves Lilly blood-thinner prasugrel

July 10, 2009
J.K. Wall
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner, according to Bloomberg News.
More
Page  << 21 22 23 24 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT